Use of bevacizumab (Avastin®) as a sterile ophthalmic solution in the treatment of hemangiomatous ocular lesions, cicatricial granuloma and pigmentary keratitis in dogs
Ophthalmology, bevacizumab, antiangiogenesis, neovascularization.
The cornea is the outermost structure of the eye. Its transparency and avascularity are vital for normal vision. It is actively maintained by the expression of anti-angiogenic and anti-lymphangiogenic factors. Corneal neovascularization is caused by inflammatory, infectious, degenerative, and traumatic diseases. Vascular endothelial growth factor (VEGF) provides a growth function of vascular cells and endothelial vessels and consequent formation of small as part of the healing process. Bevacizumab acts by blocking VEGF-A and inhibiting the growth of new blood vessels. Corticosteroid therapy is the first choice in clinical practice, but it is not always effective. This study will include 60 eyes of dogs over 1 year of age, regardless of sex and race, diagnosed with ophthalmic conditions that course with corneal neovascularization, such as: hemangiomatous lesions, pigmentary keratitis and cicatricial granuloma. These will be divided into 3 groups of G120 eyes (G2 - corticotherapy and G3 - immunomodulators). Bevacizumab will be used as a topical solution (5mg/ml), 3 times a day, for up to 4 months. Efficacy will be evaluated in a comparative way with corticosteroid therapy and the use of immunomodulators, through careful and periodic ophthalmic examinations. Based on what is presented in the literature, it is assumed that bevacizumab has high efficacy, good tolerance and affordable cost, advantages that justify the objective of this study.